Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses.

Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. 

Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio.

Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.


Therapeutics

Life Sciences

Biotechnology

Imcyse SA

Denis Bedoret

Jean van Rampelbergh

Antoon van Oosterhout

Hugues Wallemacq

Andrew Mackie

Management

Leadership Team

Scientific Research and Development

��

Teams at Imcyse SA

Management

Leadership Team

Scientific Research and Development

��������

Teams at Imcyse SA

Management

Leadership Team

Scientific Research and Development

��